Brooks Laboratories (BOM:533543) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 30, 2026)


BOM:533543 Brooks Laboratories Ltd BOM:533543
59 GF Score
Price ₹69.95
GF Value ₹117.69
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Brooks Laboratories Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Brooks Laboratories's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BOM:533543 vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brooks Laboratories Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Brooks Laboratories's Margin of Safety % (DCF Earnings Based) falls into.


BOM:533543
59GF Score
Brooks Laboratories Ltd BOM:533543
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Brooks Laboratories (BOM:533543) Overvalued in 2026?

Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued. The current stock price of ₹69.95 is trading 40.6% below its estimated GF Value™ of ₹117.69. GuruFocus considers Brooks Laboratories to be Significantly Undervalued.

Key valuation signals for BOM:533543:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹117.69 vs. price of ₹69.95 (40.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brooks Laboratories Business Description

Other Exchanges BROOKS:India
Address Near Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
59GF Score

Get the complete analysis for BOM:533543

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹69.95
Price
₹117.69
GF Value